MET-EGFR dimerisation in lung adenocarcinoma is dependent on EGFR mutations and altered by MET kinase inhibition
Prognosis in advanced stage lung cancer is extremely poor with few effective therapies. EGFR tyrosine kinase inhibitors (TKIs) have high response rates in patients with activating EGFR mutations and are now an established part of therapy in selected patients. Such advances herald a previously unprec...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
King's College London (University of London)
2017
|
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.733339 |